Aspen Neuroscience, Inc., is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson disease. Aspen's therapies are based upon the scientific work of world-renowned stem cell scientist, Dr. Jeanne Loring, who has developed a novel method for autologous neuron replacement.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/01/20 | $70,000,000 | Series A |
ARCH Venture Partners Domain Associates Frazier Healthcare Partners OrbiMed Advisors  Sam Altman Section 32 | undisclosed |
